Globus Medical, Inc. (NYSE:GMED) Q4 2021 Earnings Conference Call February 17, 2022 4:30 PM ET Company Participants Brian Kearns - SVP, Business Development & IR David Demski - CEO, President & Director Keith Pfeil - SVP & CFO Daniel Scavilla - EVP, Chief Commercial Officer & President, Trauma Conference Call Participants Matthew Taylor - UBS Shagun Chadha - RBC Capital Markets Matthew O'Brien - Piper Sandler David Saxon - Needham & Company Craig Bijou - Bank of America Merrill Lynch Ryan Zimmerman - BTIG K ...

Globus Medical, Inc. (NYSE:GMED) Q3 2021 Results Conference Call November 4, 2021 4:30 PM ET Company Participants Brian Kearns - SVP, Business Development and IR Dave Demski - President and CEO Dan Scavilla - EVP and Chief Commercial Officer Keith Pfeil - SVP and CFO Conference Call Participants Matt Miksic - Credit Suisse Matt Taylor - UBS David Saxon - Needham & Company Sam Brodovsky - Truist Korinne Wolfmeyer - Piper Sandler Steven Lichtman - Oppenheimer & Company Operator Welcome to the Globus Medical’s ...

OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

Globus Medical, Inc. (NYSE:GMED) Q2 2021 Earnings Conference Call August 4, 2021 4:30 PM ET Company Participants Kelly Huller – Senior Vice President-General Counsel Dave Demski – President and Chief Executive Officer Keith Pfeil – Senior Vice President and Chief Financial Officer Dan Scavilla – Executive Vice President and Chief Commercial Officer Conference Call Participants Shagun Singh – Wells Fargo Matt Miksic – Credit Suisse Richard Newitter – SVB Leerink Kyle Rose – Canaccord John Lee – UBS Drew Rani ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 2560 General Armistead Avenue, Audubon, PA 19403 ( ...

Globus Medical, Inc. (NYSE:GMED) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET Company Participants Brian Kearns - Senior Vice President of Business Development and Investor Relations Dave Demski - President and Chief Executive Officer Keith Pfeil - Senior Vice President and Chief Financial Officer Dan Scavilla - Executive Vice President, Chief Commercial Officer and President, Trauma Conference Call Participants Matt Miksic - Credit Suisse Kaila Krum - Truist Securities Steven Lichtman - Oppenh ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 04-3744954 (State or oth ...

Globus Medical, Inc. (NYSE:GMED) Q4 2020 Earnings Conference Call February 17, 2021 4:30 PM ET Company Participants Brian Kearns - Senior Vice President of Business Development and Investor Relations David Demski - President and Chief Executive Officer Keith Pfeil - Senior Vice President and Chief Financial Officer Daniel Scavilla - Executive Vice President and Chief Commercial Officer Conference Call Participants Shagun Chadha - Wells Fargo Securities, LLC Matthew Henriksson - Citigroup Inc Matthew Miksic ...

Product Development and Innovation - Globus Medical launched 10 new products in 2020 and has a range of new products in various stages of development, expecting to maintain a rapid rate of new product launches [20]. - The company has introduced 220 products since its inception in 2003, focusing on innovative musculoskeletal solutions [22]. - The ExcelsiusGPS® platform, a robotic guidance and navigation system, is expected to serve as a foundation for future clinical applications using artificial intelligence and augmented reality [31]. - The company employs an integrated team approach to product development, which allows for rapid product conception to launch [33]. - Significant investments have been made in product development and research capabilities to keep pace with rapid technological advancements in the market [35]. - The company must enhance and broaden its product offerings to effectively compete and meet changing customer demands [120]. International Sales and Market Expansion - International sales accounted for approximately 15.8% of total sales during the year ended December 31, 2020, with plans to expand presence in existing and new international markets [19]. - The company has a direct or distributor sales presence in 50 countries outside the United States as of December 31, 2020, and aims to increase its international sales force [27]. - International operations account for approximately 15.8% of total net sales, with significant revenues generated in Japan, the Euro zone, United Kingdom, and Australia [186]. - The company intends to expand international marketing but faces challenges in obtaining regulatory approvals in various jurisdictions [176]. Regulatory Compliance and Risks - The FDA regulates the company's medical devices and human tissue products, requiring pre-market clearance or approval for commercial distribution [58]. - The company is subject to extensive regulatory scrutiny, and any adverse actions by the FDA could materially affect its business operations and financial results [65]. - International sales of medical devices require compliance with varying foreign government regulations, which may differ significantly from FDA requirements [66]. - The upcoming EU Medical Device Regulation (MDR 2017/745) will replace the current directive, increasing technical documentation requirements and potentially altering product classifications [70]. - The company must comply with numerous international laws and regulations to market products outside the United States, which could impact its operations [149]. - The company is subject to extensive governmental regulations in both the U.S. and international markets, impacting product marketing and compliance [88]. Financial Performance and Growth Strategies - The company reported net sales of $789.0 million in 2020, indicating rapid growth since inception [188]. - The company intends to substantially increase operating expenses to expand sales coverage, marketing capabilities, and conduct clinical trials [187]. - Future growth will depend on the success of growth strategies, which are uncertain and may not be achieved [188]. - The company faces risks from currency exchange rate fluctuations that could adversely affect profitability [186]. Competition and Market Position - The company competes with major players such as Medtronic, Stryker, and Zimmer Biomet, which may develop alternative treatments or products that could impact market share [40]. - The musculoskeletal devices industry is characterized by intense competition, with major competitors including Medtronic, DePuy Synthes, and Stryker, which may affect the company's market position [107]. - The proliferation of physician-owned distributorships (PODs) may increase pricing pressure and reduce the company's competitiveness in the market [114]. Supply Chain and Manufacturing - The company has expanded its in-house manufacturing capabilities, with a significant portion of implant products manufactured in Eagleville, Pennsylvania, and regenerative biologics processed in San Antonio, Texas [42]. - The company utilizes a small number of carefully selected suppliers for key products to ensure reliability and quality, with all suppliers providing ISO-13485 certified implants [44]. - The company relies on a limited number of third-party suppliers for its Musculoskeletal Solutions products, which could impact its operations [88]. - The company relies on less than five third-party suppliers for allograft implants and products, which poses risks related to pricing, availability, quality, and delivery schedules [166]. Legal and Liability Risks - The company faces potential legal liabilities and reputational harm if its products cause unexpected complications or negative effects [119]. - There is a risk of product liability claims due to the nature of medical device manufacturing, which could result in significant legal expenses and harm to the company's reputation [206]. - Any product liability claims could increase insurance costs and may affect the company's ability to secure adequate coverage in the future [208]. - The company may incur substantial costs from intellectual property litigation, which could harm financial resources and reputation [201]. Management and Governance - As of December 31, 2020, executive officers and directors collectively owned approximately 74.7% of the voting power of the company's outstanding capital stock [209]. - David C. Paul, the Executive Chairman, controlled approximately 22.5% of the Class A and Class B common stock, representing about 74.4% of the voting power [210]. - The concentration of ownership may lead to conflicts of interest between executive officers and other stockholders, potentially harming the value of Class A common stock [211]. - The company qualifies as a "controlled company" under New York Stock Exchange rules, allowing it to take advantage of exemptions from certain corporate governance requirements [211].

Globus Medical, Inc. (NYSE:GMED) Q3 2020 Results Conference Call October 28, 2020 4:30 PM ET Company Participants Brian Kearns - Senior Vice President of Business Development and Investor Relations Dave Demski - President and Chief Executive Officer Dan Scavilla - Executive Vice President and Chief Commercial Officer Keith Pfeil - Senior Vice President and Chief Financial Officer Conference Call Participants Matt Miksic - Crédit Suisse Shagun Singh - Wells Fargo David Lewis - Morgan Stanley Richard Newitter ...